3D Systems and Theradaptive, a biopharmaceutical company announced they have entered a commercial agreement naming 3D Systems as Theradaptive’s exclusive 3D printing partner. The companies intend to deliver a novel approach to promote bone and tissue growth using Theradaptive’s unique protein-based material-binding variants to coat 3D Systems’ 3D-printed medical devices. This solution has the potential to provide patients with an opportunity for improved healing and thus better outcomes. “This agreement enables an exciting technological convergence of 3D Systems’ cutting-edge advances in orthopedic and soft tissue additive manufacturing and Theradaptive’s material-binding regenerative therapeutics,” said Luis Alvarez, CEO and founder of Theradaptive. “Uniting these two world-class technologies promises to provide safer and more effective treatment options for patients who currently have few options. This partnership sets the stage for many new products that will have the potential to significantly improve patient care.” ..In addition to being named as Theradaptive’s exclusive 3D printing partner, 3D Systems also made an $8M investment in the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DDD:
- 3D Systems & Theradaptive Establish Commercial Partnership to Advance Orthopedic & Soft Tissue Repair Using Breakthrough Regenerative Therapeutics
- 3D Systems Corp (DDD) Q2 Earnings Cheat Sheet
- 3D Systems Announces Date of Second Quarter 2023 Financial Results
- Stratasys comments on press release issued by 3D Systems
- 3D Systems targets August 4 for completion of merger talks with Stratasys